BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Common Stock Warrants - ECPv6.0.9//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://commonstockwarrants.com
X-WR-CALDESC:Events for Common Stock Warrants
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210830T170000
DTEND;TZID=America/New_York:20210830T170000
DTSTAMP:20260419T021901
CREATED:20210728T150508Z
LAST-MODIFIED:20210728T150513Z
UID:691472-1630342800-1630342800@commonstockwarrants.com
SUMMARY:Grid Dynamics Completes Redemption of Public Warrants (Nasdaq: GDYN; GDYNW) -END
DESCRIPTION:Grid Dynamics Holdings\, Inc. (Nasdaq: GDYN; GDYNW) (“Grid Dynamics”)\, a leader in enterprise-level digital transformation\, today announced that holders of its 2\,773\,141 outstanding public warrants (the “Public Warrants”) to purchase shares of its common stock\, $0.0001 par value per share (the “Common Stock”) will have until 5:00 p.m.\, New York City time\, on August 30\, 2021 (the “Redemption Date”) to exercise their Public Warrants. The Public Warrants are exercisable for an aggregate of 2\,773\,141 shares of Common Stock at a price of $11.50 per share\, representing a total of approximately $31.9 million in potential proceeds to Grid Dynamics. \n\n\n\nPursuant to the terms of the agreements governing the rights of the holders of the Public Warrants\, Grid Dynamics is entitled to redeem all of the outstanding Public Warrants for a redemption price of $0.01 per Public Warrant (the “Redemption Price”) if the last sales price of the Common Stock is at least $18.00 per share on each of twenty (20) trading days within the thirty (30) trading-day period ending on the third trading day prior to the date on which a notice of redemption is given. This share price performance target has been met. Any Public Warrants that remain unexercised immediately after 5:00 p.m.\, New York City time\, on August 30\, 2021 will be void and no longer exercisable\, and the holders of those Public Warrants will be entitled to receive $0.01 per Public Warrant. \n\n\n\nHolders of Public Warrants in “street name” should immediately contact their broker to determine their broker’s procedure for exercising their Public Warrants since the process to exercise is voluntary. Brokers will likely have an earlier deadline for beneficial holders to exercise their Public Warrants than the deadline for registered holders set forth above. If a holder of a Public Warrant does not wish for its Public Warrant to be redeemed\, it must exercise such Public Warrant before 5:00 p.m. New York City time on the Redemption Date. \n\n\n\nThe Public Warrants were issued under the Warrant Agreement\, dated as of October 4\, 2018 (the “Warrant Agreement”)\, by and between Grid Dynamics’ predecessor company\, ChaSerg Technology Acquisition Corp.\, and Continental Stock Transfer & Trust Company\, as warrant agent (the “Warrant Agent”). \n\n\n\nAs a result of the redemption\, the Public Warrants will cease to be traded on the Nasdaq effective August 30\, 2021. \n\n\n\nGrid Dynamics also announced that none of its “Private Placement Warrants” or “Working Capital Warrants” remained outstanding. \n\n\n\nNone of Grid Dynamics\, its board of directors or employees has made or is making any representation or recommendation to any holder of the Public Warrants as to whether to exercise or refrain from exercising any Public Warrants. \n\n\n\nThe shares of Common Stock underlying the Public Warrants have been registered by Grid Dynamics under the Securities Act of 1933\, as amended\, and are covered by a registration statement filed with\, and declared effective by\, the Securities and Exchange Commission (Registration No. 333‑238202). \n\n\n\nQuestions concerning redemption and exercise of the Public Warrants can be directed to Continental Stock Transfer & Trust Company\, 1 State Street\, 30th Floor\, New York\, New York 10004\, Attention: Compliance Department\, telephone number (212) 509-4000. \n\n\n\nNo Offer or Solicitation \n\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any offer of any of Grid Dynamics’s securities in any jurisdiction in which such offer\, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. \n\n\n\nAbout Grid Dynamics Holdings\, Inc. \n\n\n\nGrid Dynamics (Nasdaq: GDYN) is a digital-native technology services provider that accelerates growth and bolsters competitive advantage for Fortune 1000 companies. Grid Dynamics provides digital transformation consulting and implementation services in omnichannel customer experience\, big data analytics\, search\, artificial intelligence\, cloud migration\, and application modernization. Grid Dynamics achieves high speed-to-market\, quality\, and efficiency by using technology accelerators\, an agile delivery culture\, and its pool of global engineering talent. Founded in 2006\, Grid Dynamics is headquartered in Silicon Valley with offices across the US\, UK\, Netherlands\, Mexico\, Central\, and Eastern Europe. To learn more about Grid Dynamics\, please visit www.griddynamics.com. \n\n\n\nForward Looking Statements \n\n\n\nThis communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are not historical facts\, and involve risks and uncertainties that could cause actual results of Grid Dynamics to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology\, including the words “believes\,” “estimates\,” “anticipates\,” “expects\,” “intends\,” “plans\,” “may\,” “will\,” “potential\,” “projects\,” “predicts\,” “continue\,” or “should\,” or\, in each case\, their negative or other variations or comparable terminology. These forward-looking statements include\, without limitation\, statements regarding the redemption of the Public Warrants and the expected proceeds from the exercise of the Public Warrants. \n\n\n\nThese forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Grid Dynamics’s control and are difficult to predict. Factors that may cause such differences include\, but are not limited to\, potential exercises of the Public Warrants and other risks and uncertainties indicated in Grid Dynamics filings with the SEC. \n\n\n\nGrid Dynamics cautions that the foregoing list of factors is not exclusive. Grid Dynamics cautions readers not to place undue reliance upon any forward-looking statements\, which speak only as of the date made. Grid Dynamics does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events\, conditions or circumstances on which any such statement is based. Further information about factors that could materially affect Grid Dynamics\, including its results of operations and financial condition\, is set forth under the “Risk Factors” section of the Company’s quarterly report on Form 10-Q filed May 6\, 2021 and in other periodic filings Grid Dynamics makes with the SEC. \n\n\n\n\n\n\n\nContacts\n\n\n\nGrid Dynamics Investor Relations:investorrelations@griddynamics.com
URL:https://commonstockwarrants.com/event/grid-dynamics-completes-redemption-of-public-warrants-nasdaq-gdyn-gdynw-end/
CATEGORIES:Warrant Redemptions
ATTACH;FMTTYPE=image/png:https://commonstockwarrants.com/wp-content/uploads/2021/07/GDYN_logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210830T170000
DTEND;TZID=America/New_York:20210830T170000
DTSTAMP:20260419T021901
CREATED:20210730T124654Z
LAST-MODIFIED:20210730T142446Z
UID:691555-1630342800-1630342800@commonstockwarrants.com
SUMMARY:Cerevel Therapeutics Completes Redemption of Public Warrants (NASDAQ: CERE\, CEREW) -END
DESCRIPTION:Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”)\, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases\, today announced that on August 30\, 2021 at 5:00 p.m. ET\, it will redeem all of its outstanding public warrants to purchase shares of the Company’s common stock that were issued under the Warrant Agreement\, dated as of June 9\, 2020\, by and between the Company (f/k/a ARYA Sciences Acquisition Corp II) and Continental Stock Transfer & Trust Company (“Continental”)\, as warrant agent. \n\n\n\nEach such public warrant may be exercised by the holder thereof to purchase one share of the Company’s common stock at the exercise price of $11.50 per public warrant. Any such public warrants that remain unexercised following 5:00 p.m. ET on August 30\, 2021 will be void and no longer exercisable\, and the holders of those public warrants will be entitled to receive only the redemption price of $0.01 per warrant. As a result of the redemption\, the public warrants will cease to be traded on Nasdaq following the close of trading on August 30\, 2021. \n\n\n\nBeneficial holders seeking to exercise public warrants should contact their brokerage firm as soon as possible to process the warrant exercise in advance of the redemption date. Brokers may have an earlier deadline for beneficial holders to exercise their public warrants than the deadline set forth above. \n\n\n\nUnder the terms of the Warrant Agreement\, the Company is entitled to redeem all of such outstanding public warrants if the last sale price of the Company’s common stock reported is at least $18.00 per share on each of twenty trading days within a thirty trading day period. This share price performance requirement was satisfied as of July 27\, 2021. Warrants to purchase common stock that were issued under the Warrant Agreement in a private placement and still held by initial holders thereof or their permitted transferees are not subject to this redemption. \n\n\n\nContinental\, in its capacity as warrant agent\, has delivered a notice of redemption to each of the registered holders of such outstanding public warrants on behalf of the Company.  The shares of common stock underlying such public warrants have been registered by the Company under the Securities Act of 1933\, as amended\, and are covered by a registration statement filed on Form S-1 with\, and declared effective by\, the Securities and Exchange Commission (File No. 333-250964).  \n\n\n\nQuestions concerning redemption and exercise of such public warrants can be directed to Georgeson\, 1290 Avenue of the Americas\, 9th Floor\, New York\, NY 10104\, telephone number (888) 663-7851. \n\n\n\nNone of the Company\, its board of directors or employees have made or are making any representation or recommendation to any warrant holder as to whether to exercise or refrain from exercising any warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities and shall not constitute an offer\, solicitation or sale in any jurisdiction in which such offering\, solicitation or sale would be unlawful. \n\n\n\nAbout Cerevel Therapeutics \n\n\n\nCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases\, including Parkinson’s\, epilepsy\, schizophrenia\, and substance use disorder. Headquartered in Cambridge\, Mass.\, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts\, external collaborations\, or potential acquisitions. For more information\, visit www.cerevel.com. \n\n\n\nForward-Looking Statements \n\n\n\nThis press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases\, you can identify forward-looking statements by the following words: “may\,” “will\,” “could\,” “would\,” “should\,” “expect\,” “intend\,” “plan\,” “anticipate\,” “believe\,” “estimate\,” “predict\,” “project\,” “potential\,” “continue\,” “ongoing” or the negative of these terms or other comparable terminology\, although not all forward-looking statements contain these words. These statements involve risks\, uncertainties and other factors that may cause actual results\, levels of activity\, performance\, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release\, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future\, about which we cannot be certain. Forward-looking statements in this press release include\, but are not limited to\, express or implied statements regarding the terms of the redemption and the amount of redemption requests made by holders of public warrants. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore\, if the forward-looking statements prove to be inaccurate\, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties\, including\, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing\, progress and results of ongoing or planned clinical trials; other impacts of COVID-19\, including operational disruptions or delays or to our ability to raise additional capital; whether and when\, if at all\, our product candidates will receive approval from the FDA or other regulatory authorities\, and for which\, if any\, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings\, including those under the heading “Risk Factors” in our Quarterly Report on Form 10-Q filed with the SEC on May 17\, 2021 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements\, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame\, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However\, while we may elect to update these forward-looking statements at some point in the future\, we have no current intention of doing so except to the extent required by applicable law. You should\, therefore\, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. \n\n\n\nMedia Contact:Kate ContrerasReal Chemistrykcontreras@realchemistry.com \n\n\n\nInvestor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com
URL:https://commonstockwarrants.com/event/cerevel-therapeutics-completes-redemption-of-public-warrants-nasdaq-cere-cerew-end/
CATEGORIES:Warrant Redemptions
ATTACH;FMTTYPE=image/png:https://commonstockwarrants.com/wp-content/uploads/2021/07/CEREVEL_logo.png
END:VEVENT
END:VCALENDAR